drugset / Trial / NCT00003356
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining rituximab and interleukin-2 intreating patients who have low-grade mantle cell lymphoma or follicular lymphoma.
Timeline
- Start
- 1997-11
- Primary completion
- 2002-05
- Completion
- 2002-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |